BNTX
BioNTech SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive late-stage oncology readouts and clear partnership/licensing deals for next-gen mRNA assets lead to rapid re-rating; commercial launches or label expansions accelerate revenue and justify premium multiples.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.7.
What can break
Clinical/regulatory setbacks for oncology programs
Momentum
24
Value
52
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $115.00 · Bull $160.00 · Bear $75.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $120.99
Why
Momentum24 · Δ7d -14.1
Value52 · Δ7d -0.0
Sentiment73 · Δ7d -7.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
24
26% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
+8.5
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.0
Sentiment
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.7
Δ21d
-2.0
Why this grade
Composite grade C. Momentum 23.5 / Value 51.8 / Sentiment 73.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$23.31B
Beta
1.49
Shares Out
252.88M
P/E (TTM) · Derived
-17.4
P/S (TTM)
6.30
P/FCF (TTM) · Derived
17.68
Rev YoY
-28.2%
EPS YoY
+35.1%
Gross Margin
+73.3%
Op Margin
-29.6%
Net Debt
-$17.12B
Current Ratio
8.80
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology